Cargando…

No significant association of type 2 diabetes‐related genetic risk scores with glycated haemoglobin levels after initiating metformin or sulphonylurea derivatives

AIM: To explore the added value of diabetes‐related genetic risk scores (GRSs) to readily available clinical variables in the prediction of glycated haemoglobin (HbA1c) levels after initiation of glucose‐regulating drugs. MATERIALS AND METHODS: We conducted a cohort study in people with type 2 diabe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martono, Doti P., Heerspink, Hiddo J.L., Hak, Eelko, Denig, Petra, Wilffert, Bob
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6772120/ https://www.ncbi.nlm.nih.gov/pubmed/31168905 http://dx.doi.org/10.1111/dom.13803

Ejemplares similares

Predicting short‐ and long‐term glycated haemoglobin response after insulin initiation in patients with type 2 diabetes mellitus using machine‐learning algorithms
por: Nagaraj, Sunil B., et al.
Publicado: (2019)

National Differences in Requirements for Ethical and Competent Authority Approval for a Multinational Vaccine Trial under the EU Directive 2001/20/EC
por: van Doorn, Eva, et al.
Publicado: (2015)

Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal function and sulphonylurea metabolite group: population based cohort study
por: van Dalem, Judith, et al.
Publicado: (2016)

What’s next after metformin? focus on sulphonylurea: add-on or combination therapy
por: Lim, Phei C., et al.
Publicado: (2015)

Standardizing the haemoglobin glycation index
por: Hempe, James M., et al.
Publicado: (2021)

Precision medicine approaches for diabetic kidney disease: opportunities and challenges
por: Tye, Sok Cin, et al.
Publicado: (2021)

Erratum to: Precision medicine approaches for diabetic kidney disease: opportunities and challenges
por: Tye, Sok Cin, et al.
Publicado: (2022)

Impact of Drug-Gene-Interaction, Drug-Drug-Interaction, and Drug-Drug-Gene-Interaction on (es)Citalopram Therapy: The PharmLines Initiative
por: Bahar, Muh. Akbar, et al.
Publicado: (2020)

Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin‐naïve people with Type 2 diabetes: the DUAL IV trial
por: Rodbard, H. W., et al.
Publicado: (2016)

The impact of CYP2D6 mediated drug–drug interaction: a systematic review on a combination of metoprolol and paroxetine/fluoxetine
por: Bahar, Muh. Akbar, et al.
Publicado: (2018)

d-Ribose as a Contributor to Glycated Haemoglobin
por: Chen, Xixi, et al.
Publicado: (2017)

Identification of major cardiovascular events in patients with diabetes using primary care data
por: Pouwels, Koen Bernardus, et al.
Publicado: (2016)

Pharmacy-based predictors of non-adherence, non-persistence and reinitiation of antihypertensive drugs among patients on oral diabetes drugs in the Netherlands
por: Alfian, Sofa D., et al.
Publicado: (2019)

Discontinuation and dose adjustment of metoprolol after metoprolol‐paroxetine/fluoxetine co‐prescription in Dutch elderly
por: Bahar, Muh. Akbar, et al.
Publicado: (2018)

Sex disparities in the effect of statins on lipid parameters: The PharmLines Initiative
por: Hunt, Nicholas B., et al.
Publicado: (2022)

Patients’ Attitudes Towards Deprescribing Alpha-Blockers and Their Willingness to Participate in a Discontinuation Trial
por: Edelman, Malou, et al.
Publicado: (2019)

Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy
por: Vilsbøll, Tina, et al.
Publicado: (2018)

Prediction of the Effects of Empagliflozin on Cardiovascular and Kidney Outcomes Based on Short-Term Changes in Multiple Risk Markers
por: Tye, Sok Cin, et al.
Publicado: (2022)

Association between Adherence to Guideline-Recommended Preventive Medications and In-Hospital Mortality among Non-Reperfused ST-Elevation Myocardial Infarction Patients Admitted to a Tertiary Care Academic Center in a Developing Country
por: Irawati, Sylvi, et al.
Publicado: (2020)

Prevalence and Accuracy of Information on CYP2D6, CYP2C19, and CYP2C9 Related Substrate and Inhibitor Co-Prescriptions in the General Population: A Cross‐Sectional Descriptive Study as Part of the PharmLines Initiative
por: Bahar, Muh. Akbar, et al.
Publicado: (2020)

Labile glycated haemoglobin and carbamylated haemoglobin are still critical points for HbA(1c) measurement
por: Desmons, Aurore, et al.
Publicado: (2017)

Prevalence of prediabetes, and diabetes in Chandigarh and Panchkula region based on glycated haemoglobin and Indian diabetes risk score
por: Kumar, Saurabh, et al.
Publicado: (2020)

Individual variability in response to renin angiotensin aldosterone system inhibition predicts cardiovascular outcome in patients with type 2 diabetes: A primary care cohort study
por: Apperloo, Ellen M., et al.
Publicado: (2018)

When drug treatments bias genetic studies: Mediation and interaction
por: Schmidt, Amand F., et al.
Publicado: (2019)

Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea
por: Lukashevich, V, et al.
Publicado: (2014)

Concordance assessment of self-reported medication use in the Netherlands three-generation Lifelines Cohort study with the pharmacy database iaDB.nl: The PharmLines initiative
por: Sediq, Rahmat, et al.
Publicado: (2018)

Glycated Haemoglobin Levels and Its Effect on Outcomes in Cardiac Surgery
por: Ansari, Daniyal Matin, et al.
Publicado: (2022)

Cost–utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus
por: Davies, M J, et al.
Publicado: (2012)

Clinical outcomes and health care costs combining metformin with sitagliptin or sulphonylureas or thiazolidinediones in uncontrolled type 2 diabetes patients
por: Degli Esposti, Luca, et al.
Publicado: (2014)

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial
por: Wilding, J P H, et al.
Publicado: (2013)

Progression to insulin therapy among patients with type 2 diabetes treated with sitagliptin or sulphonylurea plus metformin dual therapy
por: Inzucchi, S. E., et al.
Publicado: (2015)

Addition of sulphonylurea to metformin does not relevantly change body weight: a prospective observational cohort study (ZODIAC‐39)
por: Schrijnders, Dennis, et al.
Publicado: (2016)

Optimal utilisation of sulphonylureas in resource-constrained settings
por: Naidoo, Poobalan, et al.
Publicado: (2014)

Progress and opportunities in measuring the burden of Chronic Kidney Disease
por: Vart, Priya, et al.
Publicado: (2022)

Glycated haemoglobin (HbA(1c)) for postmortem diagnosis of diabetes
por: Lepik, Delia, et al.
Publicado: (2018)

Access to insulin delivery devices and glycated haemoglobin in lower-income countries
por: Klatman, Emma Louise, et al.
Publicado: (2020)

Ferrocene-Labelled Electroactive Aptamer-Based Sensors (Aptasensors) for Glycated Haemoglobin
por: Feng, Xue-Qing, et al.
Publicado: (2021)

Efficacy of Standard and Intensive Statin Treatment for the Secondary Prevention of Cardiovascular and Cerebrovascular Events in Diabetes Patients: A Meta-Analysis
por: de Vries, Folgerdiena M., et al.
Publicado: (2014)

Indirect comparison of lixisenatide versus neutral protamine Hagedorn insulin as add-on to metformin and sulphonylurea in patients with type 2 diabetes mellitus
por: Fournier, Marie, et al.
Publicado: (2014)

Single Nucleotide Polymorphisms Associated with Metformin and Sulphonylureas’ Glycaemic Response among South African Adults with Type 2 Diabetes Mellitus
por: Masilela, Charity, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_e5aqfog087h2hvgvvv10dmti43